Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,704 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review.
Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Wells V, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Collins GS, Dawoud D, Offringa M, Ouwens M, Ross JS, Taylor RS, Ciani O. Manyara AM, et al. Among authors: stewart d. J Clin Epidemiol. 2023 Aug;160:83-99. doi: 10.1016/j.jclinepi.2023.06.013. Epub 2023 Jun 26. J Clin Epidemiol. 2023. PMID: 37380118 Free article. Review.
Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE.
Manyara AM, Davies P, Stewart D, Weir CJ, Young A, Butcher NJ, Bujkiewicz S, Chan AW, Collins GS, Dawoud D, Offringa M, Ouwens M, Ross JS, Taylor RS, Ciani O. Manyara AM, et al. Among authors: stewart d. BMJ Open. 2022 Oct 11;12(10):e064304. doi: 10.1136/bmjopen-2022-064304. BMJ Open. 2022. PMID: 36220321 Free PMC article.
A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials.
Ciani O, Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS. Ciani O, et al. Among authors: stewart d. EClinicalMedicine. 2023 Oct 17;65:102283. doi: 10.1016/j.eclinm.2023.102283. eCollection 2023 Nov. EClinicalMedicine. 2023. PMID: 37877001 Free PMC article.
Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration.
Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartsson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Manyara AM, et al. Among authors: stewart d. BMJ. 2024 Jul 9;386:e078525. doi: 10.1136/bmj-2023-078525. BMJ. 2024. PMID: 38981624 Free PMC article.
Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration.
Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartsson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH 3rd, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O. Manyara AM, et al. Among authors: stewart d. BMJ. 2024 Jul 9;386:e078524. doi: 10.1136/bmj-2023-078524. BMJ. 2024. PMID: 38981645 Free PMC article.
Priority III: top 10 rapid review methodology research priorities identified using a James Lind Alliance Priority Setting Partnership.
Beecher C, Toomey E, Maeso B, Whiting C, Stewart DC, Worrall A, Elliott J, Smith M, Tierney T, Blackwood B, Maguire T, Kampman M, Ling B, Gill C, Healy P, Houghton C, Booth A, Garritty C, Thomas J, Tricco AC, Burke NN, Keenan C, Devane D. Beecher C, et al. Among authors: stewart dc. J Clin Epidemiol. 2022 Nov;151:151-160. doi: 10.1016/j.jclinepi.2022.08.002. Epub 2022 Aug 28. J Clin Epidemiol. 2022. PMID: 36038041 Free PMC article.
Realising the full potential of data-enabled trials in the UK: a call for action.
Sydes MR, Barbachano Y, Bowman L, Denwood T, Farmer A, Garfield-Birkbeck S, Gibson M, Gulliford MC, Harrison DA, Hewitt C, Logue J, Navaie W, Norrie J, O'Kane M, Quint JK, Rycroft-Malone J, Sheffield J, Smeeth L, Sullivan F, Tizzard J, Walker P, Wilding J, Williamson PR, Landray M, Morris A, Walker RR, Williams HC, Valentine J; Data Enabled Trials Group Workshop Group members. Sydes MR, et al. BMJ Open. 2021 Jun 16;11(6):e043906. doi: 10.1136/bmjopen-2020-043906. BMJ Open. 2021. PMID: 34135032 Free PMC article. Review.
What are the most important unanswered research questions in trial retention? A James Lind Alliance Priority Setting Partnership: the PRioRiTy II (Prioritising Retention in Randomised Trials) study.
Brunsdon D, Biesty L, Brocklehurst P, Brueton V, Devane D, Elliott J, Galvin S, Gamble C, Gardner H, Healy P, Hood K, Jordan J, Lanz D, Maeso B, Roberts A, Skene I, Soulsby I, Stewart D, Torgerson D, Treweek S, Whiting C, Wren S, Worrall A, Gillies K. Brunsdon D, et al. Among authors: stewart d. Trials. 2019 Oct 15;20(1):593. doi: 10.1186/s13063-019-3687-7. Trials. 2019. PMID: 31615577 Free PMC article.
4,704 results